The
serotonin (5-hydroxytryptamine, 5-HT) transporter (SERT) plays
an essential role in the termination of serotonergic neurotransmission
by removing 5-HT from the synaptic cleft into the presynaptic neuron.
It is also of pharmacological importance being targeted by antidepressants
and psychostimulant drugs. Here, five commercial databases containing
approximately 3.24 million drug-like compounds have been screened
using a combination of two-dimensional (2D) fingerprint-based and
three-dimensional (3D) pharmacophore-based screening and flexible
docking into multiple conformations of the binding pocket detected
in an outward-open SERT homology model. Following virtual screening
(VS), selected compounds were evaluated using in vitro screening and
full binding assays and an in silico hit-to-lead (H2L) screening was
performed to obtain analogues of the identified compounds. Using this
multistep VS/H2L approach, 74 active compounds, 46 of which had <i>K</i><sub>i</sub> values of ≤1000 nM, belonging to 16
structural classes, have been identified, and multiple compounds share
no structural resemblance with known SERT binders